At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2
CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.









.png)
